Skip to main content

Table 2 Clinical details of human breast tumors utilized in this study

From: A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers

Breast tumor sample set: Origin Set A: DBCG82 b/c Set C: MDACC
Patient number 128 95
Tumor subtype
Hormone receptor (HR)-positive 42 (LumA), 27 (LumB), 17 (normal-like) 64
HER2-positive 18 (erbB2) 10
Triple (receptor)-negative 24 (basal) 21
Stage
Unknown 0 0
Ductal carcinoma in situ (DCIS) 0 3
1 1 17
2 63 46
3 64 22
4 0 7
Grade
1 19 6
2 52 38
3 30 49
Unknown 27 2
Adjuvant treatment
Tamoxifen 77 19
Aromatase inhibitor 0 38
Cytotoxic chemotherapy 51 (CMF) 65 (anthracycline and/or taxane)
Trastuzumab 0 1
  1. In the Danish DBCG82 b and c breast cancer studies (Set A), premenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus cyclophosphamide, methotrexate, and fluorouracil (CMF) or to CMF chemotherapy alone, and postmenopausal women with high-risk breast cancer were randomized to receive radiation therapy plus tamoxifen (30 mg daily for 1 year) or tamoxifen alone (PMID: 10335782)
  2. CMF cyclophosphamide, methotrexate, and fluorouracil, Lum luminal, MDACC M. D. Anderson Cancer Center